Comparative Efficacy and Relative Ranking of Psoriasis Biologics Using Real World and Clinical Trial Data

The discussion focused on the comparative efficacy and ranking of psoriasis biologics by utilizing real-world evidence alongside clinical trial data. Since 2004, treatment options for psoriasis have become increasingly targeted, leading to significant improvements in efficacy and safety. The speaker analyzed head-to-head clinical trials, network meta-analyses, and real-world evidence to highlight the effectiveness of various treatments. Key findings showed that ixekizumab (IXI) outperformed adalimumab in achieving rapid skin clearance, and alongside newer agents like bimikizumab (BIMI), demonstrated superior efficacy at earlier time points. Agent comparisons revealed that BIMI, which targets IL-17A and IL-17F, offered even faster results, albeit with some trade-offs like increased rates of oral candidiasis. Other medications like risankizumab and guselkumab also exhibited strong performance and drug survival rates, suggesting they can be effective options for patients. The analysis emphasized the importance of not only clinical trial results but also real-world data, as actual patient responses can diverge from those observed in controlled environments. Registries indicated ustekinumab had favorable long-term retention rates compared to other biologics. Recommendations for clinicians emphasized the importance of weighing risks and benefits while considering patient preferences and advancing therapies into practice.